secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2026-06-12T20:32:03+00:00
Accession:  0001193125-26-269557
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage withdraws CIRM grant application for OPC1 SCI trial; annual meeting results disclosed
--------------------------------------------------------------------------------

- Withdrew CIRM CLIN2 grant application for OPC1 after receiving comments; says DOSED clinical study unaffected.
- Shareholders elected all seven director nominees, including Michael Mulroy, Dipti Amin, and Deborah Andrews.
- Ratified Baker Tilly as auditor for FY2026 (163.8M for, 0.7M against) and approved advisory say-on-pay (88.3M for, 2.6M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/0001193125-26-269557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000119312526269557/lctx-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-269557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer